Amgen (AMGN.US) has initiated phase III clinical trial for AMG 133 for weight reduction.

On March 5th, the global clinical trial registration website ClinicalTrials showed that Amgen (AMGN.US) has initiated two Phase III clinical trials (MARITIME-1 and MARITIME-2) for AMG 133 (Maridebart Cafraglutide, MariTide), marking the entry of AMG 133 into the Phase III development stage. AMG 133 is a first-in-class antibody-peptide conjugate drug developed by Amgen, with an injection frequency of once every 4 weeks. It is composed of a fully human monoclonal antibody targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) linked to two GLP-1 analogs. It works by inhibiting GIPR and activating the GLP-1 receptor (GLP-1R) to reduce food intake, regulate metabolism, and consequently, reduce weight and lower blood sugar levels. The glucose-lowering and weight-reducing effects of AMG 133 have been preliminarily validated in Phase II studies.